Want to see AU:ALA full AI Analyst Report?
Top Page
Arovella Therapeutics Limited
(Sydney:ALA)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.06
▲(5.00% Upside)
Action:Reiterated
Date:08/22/26
The score is primarily held down by weak financial performance (minimal revenue, persistent losses, and ongoing cash burn), partially offset by a low-debt balance sheet with positive equity. Technical indicators also point to a broader downtrend with weak momentum. Valuation contributes limited support because earnings are negative and no dividend yield is provided.
Positive Factors
Minimal leverage
Minimal leverage limits interest and refinancing pressure, giving Arovella greater financial flexibility while its therapies remain in development and reducing near-term solvency risk relative to more indebted biotechs.
Negative Factors
No scalable commercial revenue
Revenue falling to zero shows that Arovella has not yet established a dependable commercial base. This leaves future value heavily dependent on clinical progress, partnerships or external financing rather than recurring product sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal leverage
Minimal leverage limits interest and refinancing pressure, giving Arovella greater financial flexibility while its therapies remain in development and reducing near-term solvency risk relative to more indebted biotechs.
Read all positive factors
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$74.95M
Dividend YieldN/A
Average Volume (3M)1.58M
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue Growth-100.00%
EPS Growth14.71%
CountryAU
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,208,851,800
10 Day Avg. Volume1,549,358
30 Day Avg. Volume1,578,675
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)5.26
Price to Sales (P/S)0.00
P/FCF Ratio-10.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Arovella Therapeutics Limited Business Overview & Revenue Model
Company Description
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several k...
How the Company Makes Money
null...
Arovella Therapeutics Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 136.00K | 17.00K | 405.90K | 295.81K |
| Gross Profit | -117.71K | 136.00K | -25.98K | -3.00M | 88.75K |
| EBITDA | -11.10M | -11.10M | -10.63M | -10.37M | -7.87M |
| Net Income | -6.92M | -7.51M | -8.75M | -10.18M | -8.62M |
Balance Sheet | |||||
| Total Assets | 15.01M | 21.60M | 13.28M | 5.47M | 9.21M |
| Cash, Cash Equivalents and Short-Term Investments | 14.35M | 20.88M | 12.71M | 5.18M | 6.07M |
| Total Debt | 0.00 | 0.00 | 0.00 | 144.80K | 144.80K |
| Total Liabilities | 857.45K | 1.52M | 2.06M | 1.69M | 1.60M |
| Stockholders Equity | 14.15M | 20.08M | 11.23M | 3.78M | 7.62M |
Cash Flow | |||||
| Free Cash Flow | -6.95M | -7.34M | -7.04M | -6.40M | -6.83M |
| Operating Cash Flow | -6.91M | -6.93M | -6.91M | -6.40M | -6.27M |
| Investing Cash Flow | -40.48K | -432.11K | -179.34K | 95.42K | -566.00K |
| Financing Cash Flow | 488.69K | 15.52M | 14.61M | 5.41M | 6.19M |
Arovella Therapeutics Limited Technical Analysis
Negative
0.06
Price Trends
0.06
Negative
0.07
Negative
0.08
Negative
Market Momentum
>-0.01
Negative
40.01
Neutral
12.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALA, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.01 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ALA.
Arovella Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$76.63M | -0.87 | -69.20% | ― | ― | -73.11% | |
45 Neutral | AU$70.45M | -9.86 | -44.93% | ― | ― | 25.27% | |
44 Neutral | AU$74.95M | -10.34 | -41.83% | ― | -100.00% | 14.71% | |
43 Neutral | AU$43.38M | -0.65 | -93.08% | ― | 116.02% | 75.56% | |
40 Underperform | AU$36.73M | -0.31 | -134.65% | ― | ― | 62.72% | |
38 Underperform | AU$116.19M | -3.31 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:ALA
Arovella Therapeutics Limited
0.06
-0.03
-29.89%
AU:IMU
Imugene
0.07
-0.21
-75.09%
AU:IMM
Immutep Ltd
0.05
-0.19
-78.72%
AU:PTX
Prescient Therapeutics Limited
0.07
0.03
65.85%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-64.29%
AU:RCE
Recce Pharmaceuticals Ltd.
0.38
-0.04
-10.71%
Arovella Therapeutics Limited Corporate Events
Arovella Details Governance Framework in 2026 Corporate Statement
Aug 20, 2026
Arovella Therapeutics has released its Corporate Governance Statement for the year ended 30 June 2026, outlining adherence to the ASX Corporate Governance Principles and Recommendations. The document details the roles of the board and management, ...
Arovella lodges 2026 corporate governance statement and Appendix 4G
Aug 20, 2026
Arovella Therapeutics Limited, an ASX-listed biotechnology company, underscores structured governance through formal board and management roles, written agreements with directors and executives, and an online governance portal. The company highlig...
Arovella Narrows Annual Loss as Net Tangible Assets Per Share Fall
Aug 20, 2026
Arovella Therapeutics Limited reported a net loss after tax of $6.9 million for the year ended 30 June 2026, an improvement from the $7.5 million loss recorded in the prior year. The company’s revenues from ordinary activities fell to zero, ...
Arovella Issues 9.7 Million Unquoted Options Under Employee Incentive Scheme
Aug 17, 2026
Arovella Therapeutics Limited has issued 9,749,387 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective 17 August 2026. The move expands the company’s pool of employee equity incentiv...
Arovella outlines strategy and ALA-101 trial timeline in investor webinar
Aug 12, 2026
Arovella Therapeutics will host an investor webinar today to brief shareholders and the market on the outcomes of its recent strategic review and priorities for advancing its iNKT cell therapy platform. The session will outline near-term clinical ...
Arovella plans investor webinar ahead of first-in-human ALA-101 trial
Aug 11, 2026
Arovella Therapeutics will host an investor webinar to update shareholders and market participants on the Board’s recent strategic review and priorities for advancing its iNKT cell therapy platform. The event will outline near-term clinical ...
Arovella Advances CAR-iNKT Programs as First Human Trial Nears
Jul 27, 2026
Arovella Therapeutics reported a transformational June quarter as it moved towards first-in-human clinical evaluation of its lead CAR-iNKT therapy, ALA-101, for relapsed or refractory CD19-positive blood cancers. The company secured ethics and gov...
Arovella options lapse, easing potential shareholder dilution
Jun 30, 2026
Arovella Therapeutics Limited, listed on the ASX under the code ALA, operates in the biotechnology and therapeutics sector. The company focuses on developing medical treatments, positioning itself within the broader life sciences market where capi...
Arovella Therapeutics Seeks ASX Quotation for Additional Shares
Jun 30, 2026
Arovella Therapeutics Limited has applied for quotation of 68,181 new ordinary fully paid shares on the ASX. The securities, to be issued on June 30, 2026 under the ALA ticker, arise from the exercise or conversion of existing options or other con...
Arovella Director Increases Indirect Stake with On-Market Share Purchase
Jun 9, 2026
Arovella Therapeutics has disclosed a change in director David John Williams’ relevant interest in the company’s securities. Through Lawn Views Pty Ltd as trustee for the Angela Williams Family Trust, Williams indirectly acquired 200,0...
Arovella strengthens clinical team ahead of first ALA-101 human trial
Jun 9, 2026
Arovella Therapeutics has bolstered its clinical capabilities ahead of first-in-human trials for its lead CAR iNKT-cell therapy, ALA-101, by appointing renowned cellular immunotherapy expert Professor Cameron Turtle to its Clinical Advisory Board....
Arovella options lapse, trimming potential dilution in capital structure
May 26, 2026
Arovella Therapeutics Limited has notified the market that 2,000,000 listed options under the code ALAAA have lapsed. The options, which were set to expire on various dates at various exercise prices, ceased on May 24, 2026, without being exercise...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.